The shelf effectiveness removes the last barrier to selling stockholder sales. Expect immediate downward pressure as Armistice Capital can now sell into the market. Monitor for a Form 424B5 prospectus supplement or a 13D amendment showing share sales. Given the going-concern warning and minimal cash, any selling could be aggressive.
Price Chart
Executive Summary
Bone Biologics' S-3 shelf registration (File No. 333-297550) became effective on July 24, 2026, enabling the resale of 6,464,792 shares by selling stockholders, primarily Armistice Capital. This unlocks massive potential dilution (357% of current shares outstanding) from warrants issued in a recent $2.7M private placement, creating severe bearish overhang for a $2M market cap company with a going-concern warning and no revenue.
Key Facts
- S-3 shelf registration (File No. 333-297550) declared effective on July 24, 2026.
- Registration covers 6,464,792 shares of common stock for resale by selling stockholders, primarily Armistice Capital.
- Shares are issuable upon exercise of warrants from a July 9, 2026 private placement that raised ~$2.7M in net proceeds.
- Potential dilution of 357% relative to current shares outstanding.
- Company has a $2M market cap, a going-concern warning from its auditor, and only $4.5M in cash as of March 31, 2026.
Financial Impact
Potential dilution of 357% of current shares outstanding from 6,464,792 newly registered shares, relative to a $2M market cap company with no revenue.
Risk Factors
- Immediate dilution overhang from selling stockholders, primarily Armistice Capital.
- Going-concern warning from auditor indicates risk of bankruptcy or further dilutive financing.
- No revenue and minimal cash ($4.5M) make the company dependent on equity markets for survival.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-002449 |
| Document: 9999999995-26-002449-index.html | 9999999995-26-002449 |
| Document: 9999999995-26-002449.txt | 9999999995-26-002449 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 25-NSE | $0.4300 | awaiting T+60 | — | $0.3770 (−12.33%) |
Jul 27, 2026 13w ago | EFFECT | $1.03 $0.4105 | ▲ +59.95% | ▲ +63.66% | $0.3770 (+63.22%) |
Jul 20, 2026 14w ago | DEFA14A | $1.11 $0.4300 | ▼ −61.26% | ▼ −65.23% | $0.3770 (−66.04%) |
Jul 17, 2026 14w ago | S-3 | $1.12 $0.4300 | ▲ +61.61% | ▲ +66.45% | $0.3770 (+66.34%) |
Jul 8, 2026 15w ago | Press Release | $1.38 $0.4754 | ▲ +65.55% | ▲ +67.94% | $0.3770 (+72.68%) |
Jul 2, 2026 16w ago | DEFA14A | $1.42 $0.4912 | ▼ −65.41% | ▼ −68.42% | $0.3770 (−73.45%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers